OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE.
Seiwert TY, et al. Among authors: dekker a.
Ann Oncol. 2019 Oct 1;30(10):1673. doi: 10.1093/annonc/mdz171.
Ann Oncol. 2019.
PMID: 31168601
Free article.
No abstract available.